The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics And Cidara Therapeutics

For Immediate Release

Chicago, IL – April 07, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Esperion Therapeutics, Inc. (NASDAQ: Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Thursday’s Analyst Blog:

Best and Worst Drug Stocks from Q1

After a tough and challenging 2016, pharma and biotech stocks have been showing signs of recovery this year. The sector started the year on a strong note with the NASDAQ Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 10.7% and 5.7%, respectively, in the first quarter of 2017.

Despite the drug pricing issue remaining a headline risk this year, investors have been gaining confidence in the sector based on strong results, R&D success and innovation, FDA approvals, ramp up in new product sales and continued strong performance from legacy products. Expectations are also high that M&As will pick up this year.

There has also been some talk about speeding up the FDA approval process. Last year, the number of new drug approvals slipped to 22, well below the 45 approvals in 2015 and 41 in 2014. President Trump said that the FDA will be streamlined and the drug approval process will be much faster. The recently signed 21st Century Cures Act is a step in this direction. With the passing of this Act, expectations are that there will be more innovation in the sector and, maybe, a surge in new drug approvals. So far in 2017, 13 drugs have been approved by the agency.

While all these factors should work in favor of the sector, challenges remain in the form of additional competition, high profile pipeline setbacks, slowdown in growth of mature products and loss of exclusivity for certain key drugs.

Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.

3 Best Performing Drug Stocks in Q1

Esperion Therapeutics, Inc. (NASDAQ: Medical-Drugs industry, which is up 1.6%.

Vertex Pharmaceuticals Incorporated (NASDAQ: Free Report ): Boston, MA-based Vertex, which holds a strong position in the cystic fibrosis (CF) market, got a boost with positive data from a couple of late-stage studies evaluating a combination of tezacaftor and Kalydeco (ivacaftor). Statistically significant improvements in lung function were observed in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Vertex plans to seek approval in the U.S. and EU in the third quarter of 2017 for the treatment of people with CF ages 12 and older who have two copies of the F508del mutation and in people who have one mutation that results in residual CFTR function and F508del mutation. While the company’s shares shot up 48% in the first quarter of the year, shares are up 54.9% YTD, outperforming the Zacks-categorized Medical-Biomedical/Genetics industry which is up 3.6% so far in 2017.

Nektar Therapeutics (NASDAQ: Nektar's Pain Drug Positive in Phase III Study; Shares Gain ). YTD, Nektar’s shares are up 71.8%.

While Nektar and Esperion are Zacks Rank #3 (Hold) stocks, Vertex is a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

2 Worst Performing Drug Stocks of Q1

Argos Therapeutics, Inc. (NASDAQ: Free Report ): Durham, NC-based Argos is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform. Argos suffered a huge setback when an interim data analysis showed that the company’s pivotal late-stage study on its most advanced pipeline candidate, rocapuldencel-T, should be discontinued for futility. The company’s shares were hit hard by this news and were down 90.8% in the first quarter and 91.8% YTD.

Cidara Therapeutics, Inc. (NASDAQ: Free Report ): San Diego, CA-based Cidara is a biotech company focused on developing novel anti-infectives including immunotherapies. Cidara suffered a setback in February on disappointing mid-stage data on CD101 topical which was being evaluated for acute vulvovaginal candidiasis (VVC). The company has decided to stop further development of the topical formulation for VVC and will instead focus its resources towards the development of the IV formulation of CD101, as well as the expansion and acceleration of the Cloudbreak immunotherapy platform. CD101 IV is currently in a mid-stage study for candidemia with results expected in the fourth quarter. Cidara’s shares declined 25% during Q1 and are down 28.4% YTD.

Now See Our Private Investment Ideas

While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on ESPR - FREE

Get the full Report on VRTX - FREE

Get the full Report on NKTR - FREE

Get the full Report on ARGS - FREE

Get the full Report on CDTX - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit Zacks Investment Research

Get The News You Want

Read market moving news with a personalized feed of stocks you care about.

Get The App

Written By: Zacks Investment Research